RU2008142359A - Композиция человеческого моноклонального антитела к igf-1r - Google Patents

Композиция человеческого моноклонального антитела к igf-1r Download PDF

Info

Publication number: RU2008142359A
Authority: RU; Russia
Prior art keywords: concentration; igf; humat; histidine; polysorbate
Prior art date: 2006-03-28

Application number

RU2008142359/15A

Other languages

English (en)

Russian (ru)

Inventor

Адельберт ГРОССМАНН (DE)

Адельберт ГРОССМАНН

Ханс-Кристиан МАЛЕР (CH)

Ханс-Кристиан МАЛЕР

Астрид ПАППЕНБЕРГЕР (CH)

Астрид ПАППЕНБЕРГЕР

Оливер Борис ШТАУХ (DE)

Оливер Борис Штаух

Ян Олаф ШТРАКЕ (DE)

Ян Олаф ШТРАКЕ

Original Assignee

Ф.Хоффманн-Ля Рош Аг (Ch)

Ф.Хоффманн-Ля Рош Аг

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-28

Filing date

2007-03-19

Publication date

2010-05-10

2007-03-19 Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)

2010-05-10 Publication of RU2008142359A publication Critical patent/RU2008142359A/ru

Links

239000000203 mixture Substances 0.000 title claims abstract 15
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract 50
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 36
229960002885 histidine Drugs 0.000 claims abstract 25
229920001213 Polysorbate 20 Polymers 0.000 claims abstract 22
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract 22
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract 22
229940068977 polysorbate 20 Drugs 0.000 claims abstract 20
239000011780 sodium chloride Substances 0.000 claims abstract 18
DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims abstract 10
229940074409 trehalose dihydrate Drugs 0.000 claims abstract 10
235000002639 sodium chloride Nutrition 0.000 claims 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
229920000858 Cyclodextrin Polymers 0.000 claims 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
235000000346 sugar Nutrition 0.000 claims 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
239000001116 FEMA 4028 Substances 0.000 claims 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
102000008100 Human Serum Albumin Human genes 0.000 claims 2
108091006905 Human Serum Albumin Proteins 0.000 claims 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
229960004853 betadex Drugs 0.000 claims 2
239000003795 chemical substances by application Substances 0.000 claims 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
-1 for example Chemical compound 0.000 claims 2
239000008103 glucose Substances 0.000 claims 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
235000011187 glycerol Nutrition 0.000 claims 2
239000007788 liquid Substances 0.000 claims 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
150000008163 sugars Chemical class 0.000 claims 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 claims 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 claims 1
102000009027 Albumins Human genes 0.000 claims 1
108010088751 Albumins Proteins 0.000 claims 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
206010006187 Breast cancer Diseases 0.000 claims 1
208000026310 Breast neoplasm Diseases 0.000 claims 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
206010009944 Colon cancer Diseases 0.000 claims 1
208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
229930091371 Fructose Natural products 0.000 claims 1
239000005715 Fructose Substances 0.000 claims 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
108010024636 Glutathione Proteins 0.000 claims 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
229930195725 Mannitol Natural products 0.000 claims 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
229920002560 Polyethylene Glycol 3000 Polymers 0.000 claims 1
239000002202 Polyethylene glycol Substances 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
229930006000 Sucrose Natural products 0.000 claims 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 1
159000000021 acetate salts Chemical class 0.000 claims 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
229940024606 amino acid Drugs 0.000 claims 1
150000001413 amino acids Chemical class 0.000 claims 1
239000003963 antioxidant agent Substances 0.000 claims 1
235000006708 antioxidants Nutrition 0.000 claims 1
239000011668 ascorbic acid Substances 0.000 claims 1
235000010323 ascorbic acid Nutrition 0.000 claims 1
229960005070 ascorbic acid Drugs 0.000 claims 1
229960000686 benzalkonium chloride Drugs 0.000 claims 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
239000012888 bovine serum Substances 0.000 claims 1
239000001110 calcium chloride Substances 0.000 claims 1
229910001628 calcium chloride Inorganic materials 0.000 claims 1
229960004926 chlorobutanol Drugs 0.000 claims 1
235000019441 ethanol Nutrition 0.000 claims 1
229930182830 galactose Natural products 0.000 claims 1
229960002442 glucosamine Drugs 0.000 claims 1
229960003180 glutathione Drugs 0.000 claims 1
235000003969 glutathione Nutrition 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
239000008101 lactose Substances 0.000 claims 1
229910001629 magnesium chloride Inorganic materials 0.000 claims 1
239000000594 mannitol Substances 0.000 claims 1
235000010355 mannitol Nutrition 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
229960003194 meglumine Drugs 0.000 claims 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
229960002216 methylparaben Drugs 0.000 claims 1
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims 1
229960003742 phenol Drugs 0.000 claims 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
229920001223 polyethylene glycol Polymers 0.000 claims 1
239000001103 potassium chloride Substances 0.000 claims 1
235000011164 potassium chloride Nutrition 0.000 claims 1
239000003755 preservative agent Substances 0.000 claims 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
229960003415 propylparaben Drugs 0.000 claims 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
239000001632 sodium acetate Substances 0.000 claims 1
235000017281 sodium acetate Nutrition 0.000 claims 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
239000005720 sucrose Substances 0.000 claims 1
150000005846 sugar alcohols Polymers 0.000 claims 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
229960004906 thiomersal Drugs 0.000 claims 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
229940074410 trehalose Drugs 0.000 claims 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
229960000281 trometamol Drugs 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

RU2008142359/15A 2006-03-28 2007-03-19 Композиция человеческого моноклонального антитела к igf-1r RU2008142359A (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06111848.5		2006-03-28
EP06111848		2006-03-28

Publications (1)

Publication Number	Publication Date
RU2008142359A true RU2008142359A (ru)	2010-05-10

Family

ID=37025222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2008142359/15A RU2008142359A (ru)	2006-03-28	2007-03-19	Композиция человеческого моноклонального антитела к igf-1r

Country Status (18)

Country	Link
EP (1)	EP1998806A1 (fr)
JP (1)	JP2009531371A (fr)
KR (1)	KR20080104160A (fr)
CN (1)	CN101410137A (fr)
AR (1)	AR060130A1 (fr)
AU (1)	AU2007229554A1 (fr)
BR (1)	BRPI0709229A2 (fr)
CA (1)	CA2647111A1 (fr)
CL (1)	CL2007000797A1 (fr)
CR (1)	CR10295A (fr)
EC (1)	ECSP088778A (fr)
IL (1)	IL193904A0 (fr)
MA (1)	MA30345B1 (fr)
MX (1)	MX2008012295A (fr)
NO (1)	NO20083895L (fr)
RU (1)	RU2008142359A (fr)
TW (1)	TW200815029A (fr)
WO (1)	WO2007110339A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101553504A (zh) *	2006-12-11	2009-10-07	豪夫迈·罗氏有限公司	Aβ抗体胃肠外制剂
GB0702888D0 (en) *	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
UA96473C2 (ru) *	2007-03-22	2011-11-10	Имклоун Ллк	Жидкая стойкая композиция, которая содержит антитело imc-а12
JP2010531340A (ja) *	2007-07-10	2010-09-24	エフ．ホフマン−ラロシュアーゲー	新規処方物
WO2009068282A1 (fr) *	2007-11-29	2009-06-04	F. Hoffmann-La Roche Ag	Agrégats d'immunoglobulines
NZ585516A (en) *	2007-12-21	2012-07-27	Hoffmann La Roche	Anti-cd20 antibody formulation
WO2010069858A1 (fr) *	2008-12-19	2010-06-24	F. Hoffmann-La Roche Ag	Composition pharmaceutique
WO2010146059A2 (fr)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA2783715A1 (fr) *	2009-12-29	2011-07-07	F. Hoffmann-La Roche Ag	Nouvelle formation d'anticorps
CA2800188A1 (fr) *	2010-05-28	2011-12-01	Novo Nordisk A/S	Compositions stables multi-doses comprenant un anticorps et un agent conservateur
US9220776B2 (en)	2011-03-31	2015-12-29	Merck Sharp & Dohme Corp.	Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
CN102363040B (zh) *	2011-10-21	2013-05-01	北京锐瑟科技有限公司	用于粘膜组织的抗微生物肽制剂
KR102266819B1 (ko)	2013-04-29	2021-06-18	에프. 호프만-라 로슈 아게	Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
JP2016528167A (ja)	2013-04-29	2016-09-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ヒトＦｃＲｎ結合改変抗体及び使用方法
CN103505729B (zh) *	2013-05-24	2015-10-28	华北制药集团新药研究开发有限责任公司	一种稳定的狂犬病毒人源抗体组合制剂
CN104707146B (zh) *	2013-12-16	2019-04-16	浙江海正药业股份有限公司	一种含有阿达木单抗的药物组合物
RU2698969C2 (ru)	2014-01-15	2019-09-02	Ф.Хоффманн-Ля Рош Аг	Варианты fc-области с улучшенной способностью связываться с белком а
US10206878B2 (en) *	2014-05-28	2019-02-19	Nono Inc.	Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
TW201628649A (zh)	2014-10-09	2016-08-16	再生元醫藥公司	減少醫藥調配物中微可見顆粒之方法
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
IL302486A (en)	2015-06-24	2023-06-01	Hoffmann La Roche	Antibodies against the transnephrine receptor with adapted affinity
US10786567B2 (en) *	2015-09-28	2020-09-29	Suzhou Suncediabiopharmaeuticals Co., Ltd.	Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja)	2015-10-02	2020-03-04	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
CN106199007B (zh) *	2016-08-03	2017-04-05	烟台普罗吉生物科技发展有限公司	蛋白保护剂
KR102369014B1 (ko)	2016-08-16	2022-03-02	리제너론 파아마슈티컬스, 인크.	혼합물로부터 개별 항체들을 정량하는 방법
ES3032778T3 (en)	2016-10-25	2025-07-24	Regeneron Pharma	Methods for chromatography data analysis
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en)	2017-05-02	2019-11-28	Merck Sharp & Dohme	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
MY203415A (en)	2017-09-19	2024-06-27	Regeneron Pharma	Methods of reducing particle formation and compositions formed thereby
TW202448568A (zh)	2018-07-02	2024-12-16	美商里珍納龍藥品有限公司	自混合物製備多肽之系統及方法
EP3876990A4 (fr)	2018-11-07	2023-09-06	Merck Sharp & Dohme LLC	Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
CN114324882B (zh) *	2020-10-12	2022-12-27	广东菲鹏生物有限公司	蛋白稳定剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0999853T3 (da) *	1997-06-13	2003-04-22	Genentech Inc	Stabiliseret antostofformulering
AR032028A1 (es) *	2001-01-05	2003-10-22	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina
ATE454137T1 (de) *	2001-07-25	2010-01-15	Facet Biotech Corp	Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
JP4473257B2 (ja) *	2003-04-02	2010-06-02	エフ．ホフマン−ラロシュアーゲー	インスリン様成長因子ｉ受容体に対する抗体及びその使用
DK1610820T4 (da) *	2003-04-04	2013-11-04	Genentech Inc	Høj-koncentration antistof- og proteinformuleringer
AR046071A1 (es) *	2003-07-10	2005-11-23	Hoffmann La Roche	Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CN1835975B (zh) *	2003-08-13	2012-11-21	辉瑞产品公司	经修饰的人类igf-1r抗体

2007
- 2007-03-19 RU RU2008142359/15A patent/RU2008142359A/ru not_active Application Discontinuation
- 2007-03-19 KR KR1020087023673A patent/KR20080104160A/ko not_active Ceased
- 2007-03-19 WO PCT/EP2007/052569 patent/WO2007110339A1/fr not_active Ceased
- 2007-03-19 MX MX2008012295A patent/MX2008012295A/es active IP Right Grant
- 2007-03-19 CN CNA2007800114320A patent/CN101410137A/zh active Pending
- 2007-03-19 BR BRPI0709229-6A patent/BRPI0709229A2/pt not_active IP Right Cessation
- 2007-03-19 AU AU2007229554A patent/AU2007229554A1/en not_active Abandoned
- 2007-03-19 JP JP2009502016A patent/JP2009531371A/ja active Pending
- 2007-03-19 EP EP07727047A patent/EP1998806A1/fr not_active Withdrawn
- 2007-03-19 CA CA002647111A patent/CA2647111A1/fr not_active Abandoned
- 2007-03-26 CL CL2007000797A patent/CL2007000797A1/es unknown
- 2007-03-26 TW TW096110388A patent/TW200815029A/zh unknown
- 2007-03-26 AR ARP070101241A patent/AR060130A1/es not_active Application Discontinuation
2008
- 2008-09-04 IL IL193904A patent/IL193904A0/en unknown
- 2008-09-11 NO NO20083895A patent/NO20083895L/no not_active Application Discontinuation
- 2008-09-17 CR CR10295A patent/CR10295A/es not_active Application Discontinuation
- 2008-09-26 EC EC2008008778A patent/ECSP088778A/es unknown
- 2008-10-20 MA MA31308A patent/MA30345B1/fr unknown

Also Published As

Publication number	Publication date
MX2008012295A (es)	2008-10-09
AU2007229554A1 (en)	2007-10-04
JP2009531371A (ja)	2009-09-03
AR060130A1 (es)	2008-05-28
KR20080104160A (ko)	2008-12-01
WO2007110339A1 (fr)	2007-10-04
CL2007000797A1 (es)	2008-01-25
BRPI0709229A2 (pt)	2011-06-28
EP1998806A1 (fr)	2008-12-10
NO20083895L (no)	2008-10-24
CA2647111A1 (fr)	2007-10-04
CR10295A (es)	2008-10-06
IL193904A0 (en)	2011-08-01
CN101410137A (zh)	2009-04-15
TW200815029A (en)	2008-04-01
MA30345B1 (fr)	2009-04-01
ECSP088778A (es)	2008-10-31

Publication	Publication Date	Title
RU2008142359A (ru)	2010-05-10	Композиция человеческого моноклонального антитела к igf-1r
RU2010129481A (ru)	2012-01-27	Препарат антитела
US8795627B2 (en)	2014-08-05	Treatment of liver disorders by administration of RAP conjugates
JP5432183B2 (ja)	2014-03-05	タンパク質およびペプチドの治療薬の経口投与に関する方法および組成物
US20190071496A1 (en)	2019-03-07	Pharmaceutical formulations of tnf-alpha antibodies
KR100942399B1 (ko)	2010-02-17	Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제
RU2009126420A (ru)	2011-01-20	Парентеральная лекарственная форма антитела к абета
CN115089704A (zh)	2022-09-23	皮下her2抗体配制剂
SG193146A1 (en)	2013-09-30	Subcutaneous anti-her2 antibody formulation
ES2866050T3 (es)	2021-10-19	Composiciones que comprenden conjugados de anticuerpos-fármaco duocarmicina
JP2010512356A5 (fr)	2011-02-03
HRP20230576T1 (hr)	2023-09-01	Rekombinantna ljudska kisela alfa-glukozidaza
CA2971414A1 (fr)	2016-06-23	Methodes de traitement d'une calcification tissulaire
JP2006137678A (ja)	2006-06-01	インターロイキン−２組成物
US12318434B2 (en)	2025-06-03	Alkaline phosphate-based oncology treatments
JP3927954B2 (ja)	2007-06-13	カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物
CA2554169A1 (fr)	2005-09-09	Imagerie de perfusion du myocarde utilisant des agonistes du recepteur d'adenosine
Lee et al.	2003	Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats
CN101721700A (zh)	2010-06-09	一种抗人Her2抗体的冻干制剂
KR20220034053A (ko)	2022-03-17	재조합 단백질의 안정적인 제형
Albertioni et al.	1995	Kinetics and metabolism of 2-chloro-2′-deoxyadenosine and 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine in the isolated perfused rat liver
CN103224557B (zh)	2014-10-01	一种长效型成纤维细胞生长因子-23拮抗剂的开发
CN115721732A (zh)	2023-03-03	抗体偶联药物的药物组合物、制剂及其制备方法、用途
US20210330801A1 (en)	2021-10-28	Novel protein drug conjugate formulation
WO2012144579A1 (fr)	2012-10-26	Préparation d'anticorps ayant la forme d'une solution

Legal Events

Date	Code	Title	Description
2011-11-10	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20110725